USFDA Flags Novo Nordisk's Wegovy Advertisement as False, Seeks Immediate Action
USFDA said the television spot misleadingly suggests that Wegovy in its pill form offers an advancement or improvement over other weight-loss drugs that belong to the class known as GLP-1s.
Written By : sheeba farhat
Published On 2026-02-11 14:49 GMT | Update On 2026-02-11 14:49 GMT
Advertisement
Bengaluru: The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk's weight-loss pill is "false or misleading", according to a letter dated February 5.
The health regulator said the television spot misleadingly suggests that Wegovy in its pill form offers an advancement or improvement over other weight-loss drugs that belong to the class known as GLP-1s.
The FDA also said the claims "live lighter" and "a way forward" misleadingly imply additional weight loss compared to other currently approved GLP-1 treatments, when this has not been demonstrated.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.